Obtaining a tissue biopsy has always been the standard for reaching both early and late-stage non-small cell lung cancer (NSCLC) diagnoses, but that’s no longer the case for all stages. See for yourself how the paradigm has changed with Dr. Edward Kim, Chair of Solid Tumor Oncology and Investigational Therapeutics at Levine Cancer Institute.

Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Chemoimmunotherapy has become more prevalent as a first-line treatment option for patients with non-small cell lung cancer (NSCLC). However, by compressing two therapies into one, we could be left with fewer alternatives if patients progress. Dr. Howard Jack West exposes these potential challenges and offers his perspective on second-line approaches in NSCLC care.

Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Proven to be both statistically and clinically significant, KEYNOTE-189 has offered pivotal outcomes for patients with non-small cell lung cancer (NSCLC). Join Dr. Howard Jack West as he analyzes the substantial influence of this clinical trial.

Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

With profound results, Keynote-189 has led to change in the vast majority of U.S.-based oncologists, so now it's time to take a closer look.

Dr. Shira Johnson welcomes Dr. Howard Jack West, who leads us on a deep dive into the clinical trial. From the study design to clinical implications, Dr. West highlights key findings, which may just unlock a new standard of care and better patient outcomes.

Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

With many factors yet to be discovered, Dr. Howard Jack West targets the clinical characteristics and molecular markers associated with disease progression in non-small cell lung cancer (NSCLC) patients. As he presents patterns observed for decades, Dr. West reveals other often underrecognized clues that drive disease progression.

Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.